

23 Nov 2021 | Interviews

QUOTED. Andrew Newland.

by

Liquid biopsy company Angle recently outlined its strategy to *Medtech Insight* as it nears regulatory announcements. See what Angle's CEO Andrew Newland said about it here.

"Well over 90% of patients who die of cancer die from secondary cancer. If you could get a hold of these cells, they could be studied to get all the information needed about the cancer's spread, and what drugs to use against it." – Andrew Newland, CEO, Angle

- Find out more: [Angle Outlines Strategy As It Nears Major Regulatory Announcements](#)

[Click here](#) for a free trial of *Medtech Insight*